View Financial HealthChimeric Therapeutics 배당 및 자사주 매입배당 기준 점검 0/6Chimeric Therapeutics 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-117.9%자사주 매입 수익률총 주주 수익률-117.9%미래 배당 수익률0%배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Dec 23Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 4.4 million.Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 4.4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 776,567,389 Price\Range: AUD 0.003 Discount Per Security: AUD 0.00018 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 690,099,278 Price\Range: AUD 0.003 Discount Per Security: AUD 0.00018 Security Features: Attached Options Transaction Features: Subsequent Direct Listing공시 • Oct 27Chimeric Therapeutics Limited, Annual General Meeting, Nov 25, 2025Chimeric Therapeutics Limited, Annual General Meeting, Nov 25, 2025. Location: at level 3, 62 lygon street, carlton, victoria 3053, Australia공시 • Oct 10Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 6.6 million.Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 6.6 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 164,307,917 Price\Range: AUD 0.004 Discount Per Security: AUD 0.00024 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,092,679,329 Price\Range: AUD 0.004 Discount Per Security: AUD 0.00024 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 387,577,500 Price\Range: AUD 0.004 Discount Per Security: AUD 0.00024 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 5,435,254 Price\Range: AUD 0.004 Discount Per Security: AUD 0.00024 Transaction Features: Subsequent Direct Listing공시 • May 20Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 6.6 million.Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 6.6 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 164,300,000 Price\Range: AUD 0.004 Discount Per Security: AUD 0.00024 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,485,700,000 Price\Range: AUD 0.004 Discount Per Security: AUD 0.00024 Security Features: Attached Options Transaction Features: Subsequent Direct Listing공시 • Apr 24Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.986015 million.Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.986015 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 197,203,052 Price\Range: AUD 0.005 Discount Per Security: AUD 0.0001 Transaction Features: Rights Offering공시 • Mar 04Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 3.1903 million.Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 3.1903 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 638,059,938 Price\Range: AUD 0.005 Discount Per Security: AUD 0.0003 Transaction Features: Rights Offering공시 • Feb 13Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.1 million.Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 20,000,000 Price\Range: AUD 0.005 Transaction Features: Subsequent Direct Listing공시 • Dec 09Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 5 million.Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 69,990,973 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 430,009,027 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 125,000,000 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Transaction Features: Subsequent Direct Listing공시 • Oct 23Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 5 million.Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 69,990,973 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 430,009,027 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 125,000,000 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Transaction Features: Subsequent Direct Listing공시 • Oct 14Chimeric Therapeutics Limited, Annual General Meeting, Nov 12, 2024Chimeric Therapeutics Limited, Annual General Meeting, Nov 12, 2024. Location: at level 3, 62 lygon street, carlton, victoria 3053 Australia공시 • Jan 18Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 7.664077 million.Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 7.664077 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 273,717,042 Price\Range: AUD 0.028 Transaction Features: Rights Offering공시 • Nov 01Chimeric Therapeutics Announces FDA Clearance of IND Application for CHM 2101Chimeric Therapeutics announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of CHM 2101, Chimeric's first in class CDH17 CAR T cell therapy for gastrointestinal cancers. The company plans to investigate CHM 2101 in a multi center, open label Phase 1A/B clinical trial for patients with advanced Colorectal Cancer, Gastric Cancer and Neuroendocrine Tumours. CHM 2101 is a 3rd generation, novel CDH 17 CAR T cell therapy that targets CDH17, a cancer target associated with poor prognosis and metastasis in the most common gastrointestinal tumors including Colorectal Cancer, gastric Cancer and Neuroendocrine Tumours. These experiments demonstrated that CHM 2101 was able to eradicate established tumours in seven cancer models with no toxicity to normal tissues. With the FDA IND clearance Chimeric will now begin the initiation of a phase 1/2 multi-site clinical trial in patients with advanced ColorectAL Cancer, Gastric Cancer and neuroendocrine Tumours. The study is planned to begin patient enrollment in 2024.공시 • Oct 16Chimeric Therapeutics Limited, Annual General Meeting, Nov 14, 2023Chimeric Therapeutics Limited, Annual General Meeting, Nov 14, 2023, at 11:01 AUS Eastern Standard Time. Location: Level 3, 62 Lygon Street, Carlton Victoria Australia Agenda: To consider and receive the financial report, the Directors' report and the auditor's report for the year ended 30 June 2023; to consider the Remuneration Report; to consider Election of Director Mr Phillip Hains; to consider Election of Director Mr Eric Sullivan; to consider and Approval of 10% capacity under Listing Rule 7.1A; to consider the Renewal of Omnibus Incentive Plan; to consider Approval to issue Incentive Options to Director Mr Eric Sullivan; to consider Ratification of agreement to issue Shares to Lind Global Fund II LP; to consider Amendment to Constitution; and to consider other matters.공시 • Aug 30Chimeric Therapeutics Limited Announces Board ChangesChimeric Therapeutics announced the appointment of Mr. Eric Sullivan as a Non-Executive Director, effective 30 August 2023. Mr. Sullivan is a senior finance and operations leader with a focus on private-to-public biotechnology company building, strategy, fundraising and financial planning. He brings with him an impressive background in the biotechnology sector, having served in senior finance and operations leadership roles across a number of high-growth public biotech companies, including bluebird bio, Merrimack Pharmaceuticals and TCR2 Therapeutics. Additionally, his experience with blue-chip private companies, such as Oncorus, Gemini Therapeutics, and Triplet Therapeutics, further underpins his expertise in financial planning, fundraising, board management and investor relations. Mr. Sullivan replaces the outgoing Ms Cindy Elkins, who is stepping down from the Chimeric Board of Directors.공시 • Aug 03Chimeric Therapeutics Limited Announces the Resignation of George Matcham as Non-Executive DirectorChimeric Therapeutics Limited announced that George Matcham has resigned as a Non-Executive Director, effective 3 August 2023. George has served on the Chimeric Board since July 2021 and has provided valued contributions to the Company.공시 • Jul 12Chimeric Therapeutics Limited Announces Board ChangesChimeric Therapeutics announces that Ms Leslie Chong has resigned from her position as Non-Executive Director to focus on her duties as Chief Executive Officer of Imugene Limited.Leslie has served on the Chimeric Board since August 2020 and has provided valued contributions and experienced counsel to the Company. Following the resignation, the Board has appointed Phillip Hains to fill a casual vacancy. Phillip is the Company's CFO and Joint Company Secretary and Principal of Melbourne based "The CFO Solution".공시 • Jun 05Chimeric Therapeutics Limited Announces Launch of New Phase 1B Glioblastoma Clinical TrialChimeric Therapeutics announced activation of a Phase 1B clinical trial in patients with recurrent and/or progressive glioblastoma multiforme (GBM) to assess the safety and efficacy of CHM 1101, the company's first in class CLTX CAR T cell therapy. The trial is now open for enrollment at the Sarah Cannon Transplant & Cellular Therapy Program at St. David's South Austin Medical Center in Austin, Texas. This Phase 1B trial, being conducted under a US IND, is a two-part clinical trial designed to determine a recommended Phase 2 dose and administration schedule. Part A of the trial will enroll 3-6 patients at the highest dose tested in the ongoing clinical trial at City of Hope Cancer Centre. In late 2023, Chimeric will assess the clinical safety and activity from the CHM 1101 clinical program. Based on a favorable review of the results of that assessment, Part B of the trial, a dose expansion cohort, will be opened to enroll 12 to 26 additional patients. Upon successful completion of the Part B dose expansion cohort, the Company intends to design and initiate a registration trial, in collaboration with global regulatory feedback. CHM 1101 (CLTX CAR T) is a first-in-class CAR T therapy that has the potential to address the high unmet medical need of patients with recurrent or progressive glioblastoma. Research to develop the intellectual property covering this CAR T cell therapy took place at City of Hope. CHM 1101 cells uniquely utilize chlorotoxin (CLTX), a peptide component of scorpion venom, as the tumor-targeting component of the chimeric antigen receptor (CAR). CHM 1101 CAR T cells have been shown in preclinical models to bind more broadly and specifically to GBM cells than other targeting domains like EGFR, HER-2 or IL-13. In preclinical models, CHM 1101 cells also demonstrated potent antitumor activity against glioblastoma while not exhibiting any off-tumor recognition of normal human cells and tissues, indicating a potentially optimal safety and efficacy profile. CHM 1101 is currently being studied in a Phase 1B clinical trial in recurrent /progressive glioblastoma. Initial positive data from the investigator-initiated Phase 1A trial has been presented on patients treated in the first two dose levels of the trial.공시 • Jan 24Chimeric Therapeutics Limited Announces Successful Completion of 28-Day Follow Up Period for 3rd Patient Cohort in Brain Cancer Phase 1 TrialChimeric Therapeutics provided an update to 22 December 2022 announcement and confirm that all patients dosed in the 3rd patient cohort in City of Hope National Medical Center's phase 1A CHM 1101 (CLTX CAR T) cell therapy clinical trial have now advanced beyond the 28-day follow up period without experiencing dose- limiting toxicities. Patients in the 3rd dose cohort received a total dose of 240 X 106 CHM 1101 (CLTX CAR T) cellsthrough dual routes of intratumoral (ICT) and intraventricular (ICV) administration. Achievement of this milestone enables the trial to advance to the 4th and final dose cohort wherein subjects will be treated with a total dose of 440 X 106 CHM 1101 CAR T cells by ICT and ICV administration. City of Hope, one of the larger cancer research and treatment organizations in the United States, initiated and is leading the current Phase 1A CHM 1101 (CLTX CAR T) cell therapy clinical trial. Chimeric Therapeutics has licensed the exclusive global rights to intellectual property covering the chlorotoxin CAR-T cells from City of Hope. The Phase 1A study aims to enroll 18-36 patients with MMP2+ recurrent or progressive GBM across four dose levels. Study objectives are to evaluate the safety and efficacy of CLTX CAR T and to establish recommended dosing for a phase 2 trial. CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours. CHM 1101 is currently being studied in a phase 1 clinical trial in recurrent /progressive glioblastoma. Initial positive data has been presented on patients treated in the first two dose levels of the trial. Additional work is being undertaken to expand CLTX to additional solid tumours, beginning with metastatic melanoma. CHM 2101 (CDH17 CAR T) is a novel, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania. Preclinical evidence for CHM 2101 was published in March 2022 in Nature Cancer. CHM 2101 (CDH17 CAR T) is currently in preclinical development with a planned phase 1 clinical trial in gastrointestinal tumours. CHM 0201 (CORE-NK platform) is a clinically validated, off the shelf natural killer (NK) cell platform. Data from the complete phase 1 clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, an additional Phase1B clinical trial investigating CHM 0201 in combination with IL2 and Vactosertib is now underway. From the CHM 0201 platform, Chimeric has initiated development of four new next generation NK and CAR NK assets with plans for phase 1 clinical trials in solid tumours and blood cancers.공시 • Jan 20Chimeric Therapeutics Announces First Patient Dosed in CHM 0201 Vactosertib TrialChimeric Therapeutics, announced that the first patient has been dosed in the CHM 0201 (CORE NK) + Vactosertib clinical trial, the first ever trial to assess NK cells in combination with Vactosertib in patients with advanced colorectal and blood cancers. The CHM 0201 (CORE NK) platform is a potential best in class NK cell platform of ex-vivo expanded non HLA-matched universal donor NK cells. The platform was previously studied in a phase 1 clinical trial that established safety with no GvHD (Graft versus Host Disease), 28-day NK cell persistence and an encouraging early efficacy signal, particularly in blood cancers where all patients achieved disease control and one patient achieved a complete response that was sustained for over 15 months at time of study publication. The objective of this new Phase 1B study is to build upon the clinical responses seen in the initial CORE NK Phase 1A clinical trial by adding Vactosertib, an oral TGF- receptor inhibitor that can potentially disrupt the TGF- signaling pathway. This new trial is being led by UH Seidman oncologist J. Eva Selfridge, MD, PhD, and Assistant Professor at Case Western Reserve University School of Medicine in Ohio and is designed to treat 12 patients with either locally advanced/metastatic colorectal cancer or relapsed/refractory blood cancers. The Phase 1B trial is currently funded without financial support from Chimeric Therapeutics.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 CHMM.F 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: CHMM.F 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Chimeric Therapeutics 배당 수익률 vs 시장CHMM.F의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (CHMM.F)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Biotechs)2.4%분석가 예측 (CHMM.F) (최대 3년)0%주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 CHMM.F 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 CHMM.F 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 CHMM.F 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: CHMM.F 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/12/04 03:24종가2024/09/06 00:00수익2024/06/30연간 수익2024/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Chimeric Therapeutics Limited는 3명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Hunter DiamondDiamond Equity Research LLCMaxim JacobsEdison Investment Researchnull nullLodge Partners Pty Ltd.
공시 • Dec 23Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 4.4 million.Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 4.4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 776,567,389 Price\Range: AUD 0.003 Discount Per Security: AUD 0.00018 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 690,099,278 Price\Range: AUD 0.003 Discount Per Security: AUD 0.00018 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
공시 • Oct 27Chimeric Therapeutics Limited, Annual General Meeting, Nov 25, 2025Chimeric Therapeutics Limited, Annual General Meeting, Nov 25, 2025. Location: at level 3, 62 lygon street, carlton, victoria 3053, Australia
공시 • Oct 10Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 6.6 million.Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 6.6 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 164,307,917 Price\Range: AUD 0.004 Discount Per Security: AUD 0.00024 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,092,679,329 Price\Range: AUD 0.004 Discount Per Security: AUD 0.00024 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 387,577,500 Price\Range: AUD 0.004 Discount Per Security: AUD 0.00024 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 5,435,254 Price\Range: AUD 0.004 Discount Per Security: AUD 0.00024 Transaction Features: Subsequent Direct Listing
공시 • May 20Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 6.6 million.Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 6.6 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 164,300,000 Price\Range: AUD 0.004 Discount Per Security: AUD 0.00024 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,485,700,000 Price\Range: AUD 0.004 Discount Per Security: AUD 0.00024 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
공시 • Apr 24Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.986015 million.Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.986015 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 197,203,052 Price\Range: AUD 0.005 Discount Per Security: AUD 0.0001 Transaction Features: Rights Offering
공시 • Mar 04Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 3.1903 million.Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 3.1903 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 638,059,938 Price\Range: AUD 0.005 Discount Per Security: AUD 0.0003 Transaction Features: Rights Offering
공시 • Feb 13Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.1 million.Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 20,000,000 Price\Range: AUD 0.005 Transaction Features: Subsequent Direct Listing
공시 • Dec 09Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 5 million.Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 69,990,973 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 430,009,027 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 125,000,000 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Transaction Features: Subsequent Direct Listing
공시 • Oct 23Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 5 million.Chimeric Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 69,990,973 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 430,009,027 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 125,000,000 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Transaction Features: Subsequent Direct Listing
공시 • Oct 14Chimeric Therapeutics Limited, Annual General Meeting, Nov 12, 2024Chimeric Therapeutics Limited, Annual General Meeting, Nov 12, 2024. Location: at level 3, 62 lygon street, carlton, victoria 3053 Australia
공시 • Jan 18Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 7.664077 million.Chimeric Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 7.664077 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 273,717,042 Price\Range: AUD 0.028 Transaction Features: Rights Offering
공시 • Nov 01Chimeric Therapeutics Announces FDA Clearance of IND Application for CHM 2101Chimeric Therapeutics announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of CHM 2101, Chimeric's first in class CDH17 CAR T cell therapy for gastrointestinal cancers. The company plans to investigate CHM 2101 in a multi center, open label Phase 1A/B clinical trial for patients with advanced Colorectal Cancer, Gastric Cancer and Neuroendocrine Tumours. CHM 2101 is a 3rd generation, novel CDH 17 CAR T cell therapy that targets CDH17, a cancer target associated with poor prognosis and metastasis in the most common gastrointestinal tumors including Colorectal Cancer, gastric Cancer and Neuroendocrine Tumours. These experiments demonstrated that CHM 2101 was able to eradicate established tumours in seven cancer models with no toxicity to normal tissues. With the FDA IND clearance Chimeric will now begin the initiation of a phase 1/2 multi-site clinical trial in patients with advanced ColorectAL Cancer, Gastric Cancer and neuroendocrine Tumours. The study is planned to begin patient enrollment in 2024.
공시 • Oct 16Chimeric Therapeutics Limited, Annual General Meeting, Nov 14, 2023Chimeric Therapeutics Limited, Annual General Meeting, Nov 14, 2023, at 11:01 AUS Eastern Standard Time. Location: Level 3, 62 Lygon Street, Carlton Victoria Australia Agenda: To consider and receive the financial report, the Directors' report and the auditor's report for the year ended 30 June 2023; to consider the Remuneration Report; to consider Election of Director Mr Phillip Hains; to consider Election of Director Mr Eric Sullivan; to consider and Approval of 10% capacity under Listing Rule 7.1A; to consider the Renewal of Omnibus Incentive Plan; to consider Approval to issue Incentive Options to Director Mr Eric Sullivan; to consider Ratification of agreement to issue Shares to Lind Global Fund II LP; to consider Amendment to Constitution; and to consider other matters.
공시 • Aug 30Chimeric Therapeutics Limited Announces Board ChangesChimeric Therapeutics announced the appointment of Mr. Eric Sullivan as a Non-Executive Director, effective 30 August 2023. Mr. Sullivan is a senior finance and operations leader with a focus on private-to-public biotechnology company building, strategy, fundraising and financial planning. He brings with him an impressive background in the biotechnology sector, having served in senior finance and operations leadership roles across a number of high-growth public biotech companies, including bluebird bio, Merrimack Pharmaceuticals and TCR2 Therapeutics. Additionally, his experience with blue-chip private companies, such as Oncorus, Gemini Therapeutics, and Triplet Therapeutics, further underpins his expertise in financial planning, fundraising, board management and investor relations. Mr. Sullivan replaces the outgoing Ms Cindy Elkins, who is stepping down from the Chimeric Board of Directors.
공시 • Aug 03Chimeric Therapeutics Limited Announces the Resignation of George Matcham as Non-Executive DirectorChimeric Therapeutics Limited announced that George Matcham has resigned as a Non-Executive Director, effective 3 August 2023. George has served on the Chimeric Board since July 2021 and has provided valued contributions to the Company.
공시 • Jul 12Chimeric Therapeutics Limited Announces Board ChangesChimeric Therapeutics announces that Ms Leslie Chong has resigned from her position as Non-Executive Director to focus on her duties as Chief Executive Officer of Imugene Limited.Leslie has served on the Chimeric Board since August 2020 and has provided valued contributions and experienced counsel to the Company. Following the resignation, the Board has appointed Phillip Hains to fill a casual vacancy. Phillip is the Company's CFO and Joint Company Secretary and Principal of Melbourne based "The CFO Solution".
공시 • Jun 05Chimeric Therapeutics Limited Announces Launch of New Phase 1B Glioblastoma Clinical TrialChimeric Therapeutics announced activation of a Phase 1B clinical trial in patients with recurrent and/or progressive glioblastoma multiforme (GBM) to assess the safety and efficacy of CHM 1101, the company's first in class CLTX CAR T cell therapy. The trial is now open for enrollment at the Sarah Cannon Transplant & Cellular Therapy Program at St. David's South Austin Medical Center in Austin, Texas. This Phase 1B trial, being conducted under a US IND, is a two-part clinical trial designed to determine a recommended Phase 2 dose and administration schedule. Part A of the trial will enroll 3-6 patients at the highest dose tested in the ongoing clinical trial at City of Hope Cancer Centre. In late 2023, Chimeric will assess the clinical safety and activity from the CHM 1101 clinical program. Based on a favorable review of the results of that assessment, Part B of the trial, a dose expansion cohort, will be opened to enroll 12 to 26 additional patients. Upon successful completion of the Part B dose expansion cohort, the Company intends to design and initiate a registration trial, in collaboration with global regulatory feedback. CHM 1101 (CLTX CAR T) is a first-in-class CAR T therapy that has the potential to address the high unmet medical need of patients with recurrent or progressive glioblastoma. Research to develop the intellectual property covering this CAR T cell therapy took place at City of Hope. CHM 1101 cells uniquely utilize chlorotoxin (CLTX), a peptide component of scorpion venom, as the tumor-targeting component of the chimeric antigen receptor (CAR). CHM 1101 CAR T cells have been shown in preclinical models to bind more broadly and specifically to GBM cells than other targeting domains like EGFR, HER-2 or IL-13. In preclinical models, CHM 1101 cells also demonstrated potent antitumor activity against glioblastoma while not exhibiting any off-tumor recognition of normal human cells and tissues, indicating a potentially optimal safety and efficacy profile. CHM 1101 is currently being studied in a Phase 1B clinical trial in recurrent /progressive glioblastoma. Initial positive data from the investigator-initiated Phase 1A trial has been presented on patients treated in the first two dose levels of the trial.
공시 • Jan 24Chimeric Therapeutics Limited Announces Successful Completion of 28-Day Follow Up Period for 3rd Patient Cohort in Brain Cancer Phase 1 TrialChimeric Therapeutics provided an update to 22 December 2022 announcement and confirm that all patients dosed in the 3rd patient cohort in City of Hope National Medical Center's phase 1A CHM 1101 (CLTX CAR T) cell therapy clinical trial have now advanced beyond the 28-day follow up period without experiencing dose- limiting toxicities. Patients in the 3rd dose cohort received a total dose of 240 X 106 CHM 1101 (CLTX CAR T) cellsthrough dual routes of intratumoral (ICT) and intraventricular (ICV) administration. Achievement of this milestone enables the trial to advance to the 4th and final dose cohort wherein subjects will be treated with a total dose of 440 X 106 CHM 1101 CAR T cells by ICT and ICV administration. City of Hope, one of the larger cancer research and treatment organizations in the United States, initiated and is leading the current Phase 1A CHM 1101 (CLTX CAR T) cell therapy clinical trial. Chimeric Therapeutics has licensed the exclusive global rights to intellectual property covering the chlorotoxin CAR-T cells from City of Hope. The Phase 1A study aims to enroll 18-36 patients with MMP2+ recurrent or progressive GBM across four dose levels. Study objectives are to evaluate the safety and efficacy of CLTX CAR T and to establish recommended dosing for a phase 2 trial. CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours. CHM 1101 is currently being studied in a phase 1 clinical trial in recurrent /progressive glioblastoma. Initial positive data has been presented on patients treated in the first two dose levels of the trial. Additional work is being undertaken to expand CLTX to additional solid tumours, beginning with metastatic melanoma. CHM 2101 (CDH17 CAR T) is a novel, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania. Preclinical evidence for CHM 2101 was published in March 2022 in Nature Cancer. CHM 2101 (CDH17 CAR T) is currently in preclinical development with a planned phase 1 clinical trial in gastrointestinal tumours. CHM 0201 (CORE-NK platform) is a clinically validated, off the shelf natural killer (NK) cell platform. Data from the complete phase 1 clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, an additional Phase1B clinical trial investigating CHM 0201 in combination with IL2 and Vactosertib is now underway. From the CHM 0201 platform, Chimeric has initiated development of four new next generation NK and CAR NK assets with plans for phase 1 clinical trials in solid tumours and blood cancers.
공시 • Jan 20Chimeric Therapeutics Announces First Patient Dosed in CHM 0201 Vactosertib TrialChimeric Therapeutics, announced that the first patient has been dosed in the CHM 0201 (CORE NK) + Vactosertib clinical trial, the first ever trial to assess NK cells in combination with Vactosertib in patients with advanced colorectal and blood cancers. The CHM 0201 (CORE NK) platform is a potential best in class NK cell platform of ex-vivo expanded non HLA-matched universal donor NK cells. The platform was previously studied in a phase 1 clinical trial that established safety with no GvHD (Graft versus Host Disease), 28-day NK cell persistence and an encouraging early efficacy signal, particularly in blood cancers where all patients achieved disease control and one patient achieved a complete response that was sustained for over 15 months at time of study publication. The objective of this new Phase 1B study is to build upon the clinical responses seen in the initial CORE NK Phase 1A clinical trial by adding Vactosertib, an oral TGF- receptor inhibitor that can potentially disrupt the TGF- signaling pathway. This new trial is being led by UH Seidman oncologist J. Eva Selfridge, MD, PhD, and Assistant Professor at Case Western Reserve University School of Medicine in Ohio and is designed to treat 12 patients with either locally advanced/metastatic colorectal cancer or relapsed/refractory blood cancers. The Phase 1B trial is currently funded without financial support from Chimeric Therapeutics.